Caption: The signing ceremony of the letter of intent for the cooperation of the Green Ribbon Liver Cancer Early Screening and Early Diagnosis Project Photo provided by the interviewee.
Recently, the 2024 Shanghai Biomedical Industry International Development Conference with the theme of "Facing the International and Going Overseas" was held. At this conference, the "Green Ribbon Liver Cancer Early Screening and Early Diagnosis Program" was announced. The program will be led by Zhongshan Hospital Affiliated to Fudan University, with Academician Fan Jia, President of Zhongshan Hospital Affiliated to Fudan University, and Zhou Jian, Vice President of Zhongshan Hospital Affiliated to Fudan University, as the main leaders, to comprehensively promote the screening of high-risk groups of liver cancer, the verification of new technologies for early screening of liver cancer, the promotion of standardized diagnosis and treatment of liver cancer, and the popularization of popular science education for public diseases, so as to help achieve the important goal of overall cancer prevention and treatment in China.
With high incidence and low survival rate, liver cancer is a serious threat to the health of our people.
China is a big country with liver cancer, accounting for nearly 50% of the world's new cases and deaths every year. In 2022, there were 36 new patients with liver cancer770,000 cases, ranking fourth among all malignant tumors, and the number of deaths was 31650,000, second only to lung cancer. Liver cancer in China is quite different from that of European and American countries in terms of quality and biological behavior. Unlike nonalcoholic steatohepatitis-associated liver cancer in the United States and hepatitis C-associated liver cancer in Japan, hepatitis B-associated liver cancer accounts for a larger proportion in China. There are nearly 90 million hepatitis B virus carriers in China, of which about 28 million are hepatitis B patients, and the huge population base of hepatitis B carriers has become the main reason for the high incidence of liver cancer in China.
Professor Zhou Jian, vice president of Zhongshan Hospital affiliated to Fudan University, introduced that due to the insidious onset of liver cancer and the low early diagnosis rate, 70%-80% of patients have been diagnosed with locally advanced or distant metastasis, which is difficult for these patients, with short survival and poor quality of life. From 2012 to 2015, the five-year survival rate of liver cancer in China was only 121%, which is much lower than overall cancer survival and other cancers of the digestive tract. About 55% of liver cancer patients are diagnosed at an advanced stage, compared to only about 15% and 5% in the United States and Japan.
The prevention and treatment of liver cancer focuses on "early", and early screening and early diagnosis can help improve the overall survival rate of liver cancer.
Liver cancer has clear risk factors, such as hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, alcohol (ethanol), etc., and the evolution of liver cancer is a relatively long-term process (viral hepatitis, liver cirrhosis, liver cancer), so it is particularly important to try to block intervention in all aspects of the early stage through early screening and early diagnosis. The Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022) of the Chinese Society of Clinical Oncology recommend regular screening for high-risk groups of liver cancer in men over 40 years old and women over 50 years old. Scientifically identifying high-risk groups for liver cancer and formulating stratified monitoring programs are the most critical aspects of early detection, early diagnosis and improving the overall survival rate of liver cancer.
At present, there are abundant methods for liver cancer, in addition to surgery, including targeting, immunization, chemotherapy, etc., surgical resection is still the main means of liver cancer, but the risk after surgery is 50%. Except for the 30% of patients who can undergo surgical resection, the system** mainly plays a role in the diagnosis and treatment of intermediate and advanced liver cancer, with the aim of prolonging the survival time of patients.
The multidisciplinary diagnosis and treatment model (MDT) has become a recognized and efficient diagnosis and treatment mode in the field of oncology. That is, with hepatobiliary surgery as the leading, radiotherapy, interventional medicine, infection and other departments jointly participate, the multidisciplinary expert group can cooperate in diagnosis and treatment, form a patient-centered and multidisciplinary expert group as the support, help patients achieve individualized and comprehensive treatment, and can choose reasonable methods for liver cancer patients at different stages to maximize the efficacy.
Professor Zhou Jian also said that the "Green Ribbon Liver Cancer Early Diagnosis and Early Screening Program" led by Zhongshan Hospital affiliated to Fudan University hopes to comprehensively promote the screening of high-risk groups of liver cancer, the verification of new technologies for early screening of liver cancer in China, the promotion of standardized diagnosis and treatment of liver cancer, and the popularization of popular science education for public diseases with the help of the community, science and technology and enterprises in the future, so as to help achieve the important goal of overall cancer prevention and treatment in China.
Fan Jia, academician of the Chinese Academy of Sciences and president of Zhongshan Hospital affiliated to Fudan University, said that the "Green Ribbon Liver Cancer Early Screening and Early Diagnosis Program" will comprehensively promote the screening of high-risk groups of liver cancer, the verification of new technologies for early screening of liver cancer, the promotion of standardized diagnosis and treatment of liver cancer and the popularization of popular science education for public diseases, explore the threshold of standardized diagnosis and treatment of liver cancer, from "heavy screening" to "heavy screening", create a "Shanghai model" for early screening of liver cancer, actively respond to the call of "Healthy China 2030", and help achieve the important goal of overall cancer prevention and treatment in China.
The conference was hosted by the Shanghai Municipal Science and Technology Commission, organized by the Shanghai Biomedical Science and Technology Development Center and the Shanghai Biomedical Industry Promotion Center, and co-organized by AstraZeneca.
Xinmin Evening News reporter Zuo Yan.